The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis.

In 30 seconds

This randomized controlled trial investigated the impact of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in HIV/TB-coinfected adults without diabetes. The study found that metformin significantly reduced isoniazid bioavailability by 15.6% and rifampicin bioavailability by 24.0%, indicating potential alterations in drug exposure in this population.

Key findings

• Metformin reduced isoniazid bioavailability by 15.6% (95% CI: 4.45-26.4%, P < 0.009).
• Rifampicin bioavailability decreased by 24.0% (95% CI: 7.83-36.3%, P < 0.007).
• The area under the curve for isoniazid decreased from 18.2 to 15.6 mg·h/L.
• Rifampicin exposure decreased from 35.9 to 27.1 mg·h/L.

Why it matters

Understanding the interaction between metformin and first-line TB drugs is crucial for optimizing treatment regimens in HIV/TB-coinfected patients, as altered drug bioavailability may affect therapeutic outcomes.